Global Respiratory Drug Market Research and Forecast 2018-2023

Global Respiratory Drug Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

The global respiratory drug market is expected to grow significantly during forecast period. Several respiratory drugs are given by inhalation, although enteral, parenteral, transdermal, or topical routes of administration may be used for some respiratory drugs. Inhalation route of administration has various advantages over systemic administration such as a smaller dose can be used, adverse effects are often reduced, the drug is delivered quickly to lung tissue or the bloodstream, administration is painless, and delivery is usually safe and convenient. The respiratory drugs are used to treat several respiratory diseases such as asthma, COPD (chronic obstructive pulmonary disease), cystic fibrosis, chronic bronchitis, emphysema and allergic rhinitis.

Browse full report at: https://www.omrglobal.com/industry-reports/respiratory-drug-market/

Major factors contributing to the growth of the global respiratory drug market include increasing prevalence of chronic respiratory diseases such as asthma and COPD. This is mainly owing to increasing smoking and pollution across the globe. Growing cases of respiratory diseases in new born and children and changing lifestyle and rise in obesity are fueling the market growth.  Moreover, innovations and development of new drugs such as Dupilumab for severe asthma is significantly contributing in the market growth. However, reimbursements and strict government regulations and limited awareness and availability are some of the factors hindering the growth of the market. Lack of awareness among population of emerging countries is hampering the growth of the global respiratory drug market. However, robust pipeline products and emerging markets is expected to fuel the market growth in the near future.

The global respiratory drug market can be segmented on the basis of drug, drug class, route of administration, and end user. The market by drug class is segmented on the basis of currently available medication options for the treatment of symptoms of respiratory disorders reduce the symptoms for disease control. Generally, six classes of drug and nasal saline are used to treat asthma, oral and topical H1-antihistamines, mast cell stabilizers (i.e., cromones), decongestants, anticholinergic agents, and leukotriene inhibitors. Medications used for asthma are characteristically administered orally or intranasally. The intranasal route allows higher concentrations of the drug to be delivered, thus minimizing systemic side effects.

The report covers:

• Comprehensive research methodology of global respiratory drug market
• This report also includes detailed and extensive market overview with key analyst insights
• Exhaustive analysis of macro and micro factors influencing the market guided by key                                 recommendations
• Analysis of regional regulations and other government policies impacting the global respiratory drug         market
• Insights about market determinants which are stimulating the global respiratory drug market
• Detailed and extensive market segments with regional distribution of forecasted revenues
• Extensive profiles and recent developments of market players

For related reports please visit: Healthcare Industry